Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Next Previous
Trial Profile

A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABT 011 (Primary)
  • Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Sponsors ASIT biotech; BioTech Tools; DMS Imaging

Most Recent Events

  • 04 Mar 2019 Results demonstrating immunologic mechanisms of gpASIT+TM immuno-therapy in a subset of patients from Belgium in this trial published in the Journal of Allergy and Clinical Immunology.
  • 12 Mar 2018 According to an ASIT biotech media release, company published new article presenting the results from this study in the scientific journal ALLERGY, the official journal of the European Academy of Allergy and Clinical Immunology (EAACI).
  • 05 Mar 2018 Results evaluating quality of life during hey fever season presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top